Monsanto, Nomad Bioscience Announce Collaboration
News Jun 29, 2016
The licensed technology enables more efficient development of edited traits and may be applied across a broad range of genome-editing technologies and project types. Nomad’s novel approach holds the promise to accelerate the development of improved agricultural products via genome editing.
“Our approach greatly increases both the efficiency of genome editing and the ability to deploy edited traits in commercial varieties, which could prove to be beneficial to the speed and scale at which potential products are developed,” said Dr. Yuri Gleba, chief executive officer and Nomad founder.
The agreement includes a three-year research project, during which scientists at Nomad will continue to expand the applicability of their technology. In addition, the agreement provides Monsanto with rights to use Nomad’s technology for research projects during the term, as well as an option for an exclusive commercial license to apply the proprietary technology in the development of agriculture products. Additional details of the agreement were not disclosed.
“Monsanto is committed to delivering best-in-class solutions to growers who face increasing challenges every year,” said Tom Adams, biotechnology lead for Monsanto. “Our collaboration with Nomad is one example of how we employ the industry’s best science through our own R&D pipeline and through strategic partnerships to continually drive agriculture innovation.”
Gene-editing technologies offer a way for scientists to develop site-directed integration of specific genes as well as the opportunity to enhance beneficial or remove undesired plant characteristics. Monsanto believes that genome-editing technologies will enable plant breeders to deliver better hybrids and varieties more efficiently, as well as offer plant scientists additional resources to deliver new improvements in plant biotechnology.
Nomad is a privately-held biotechnology company headquartered in Munich, Germany.
Back in 2009, researchers identified a herd of Awassi sheep suffering from "day blindness". As that term implies, these sheep were blind during the day (in bright light) but could see at night, in low-light conditions. After identifying the genetic basis of this blindness, researchers have now successfully used gene therapy to restore their daytime vision.READ MORE